发帖
每发1个新帖
可以获得0.5个丁当奖励
回帖

【medical-news】文迪雅对手 Actos 能减少动脉硬化

只看楼主
页码直达：
直达末页

楼主

丁香园管理员

1楼

这个帖子发布于12年零99天前，其中的信息可能已发生改变或有所发展。

Diabetes Drug Actos Slows Artery Plaque

Study Shows Reduction in Atherosclerosis in Diabetes Patients

March 31, 2008 (Chicago) -- The diabetes pill Actos beat out an older diabetes drug, Amaryl, at slowing the buildup of plaque in the heart arteries of people with type 2 diabetes and cardiovascular disease, researchers report.

Atherosclerosis, or plaque buildup in the inner lining of the arteries, is particularly aggressive in patients with diabetes, often leading to heart attacks and strokes. Nearly three-fourths of people with diabetes die from cardiovascular disease.

"This represents, to our knowledge, the first demonstration of the ability of any blood-sugar-lowering agent to slow the progression of coronary atherosclerosis in patients with diabetes," says researcher Steven E. Nissen, MD, chairman of cardiovascular medicine at Cleveland Clinic.

"This will change the paradigm of how we treat people with diabetes," he tells WebMD. "It's not how much you lower blood sugar, but how you lower it."

The study was presented at the annual meeting of the American College of Cardiology and simultaneously released online by The Journal of the American Medical Association.

How Actos and Amaryl Work
Nissen and colleagues studied more than 350 people with type 2 diabetes and cardiovascular disease. About half were given Actos, a member of a relatively new class of antidiabetic agents known as thiazolidinediones.

The rest were given Amaryl. It's a member of the class of agents known as sulfonylureas that have been available for decades and represent one of the most commonly prescribed classes of diabetic therapy.

All took medication for heart disease.

Actos and Amaryl work very differently. Actos makes the body more sensitive to insulin. Amaryl stimulates the pancreas to release more insulin.

Actos carries a "black box" warning that the drug may trigger heart failure, but it has not been linked to any increased risk of heart attack.

Actos Slows Plaque Buildup
All the participants underwent ultrasounds at the start of the study and about 18 months later to determine changes in the plaque buildup within the coronary arteries.

Results showed that Actos halted the dangerous progression of atherosclerosis and even started to reverse it, Nissen says. In contrast, plaque continued to build up in the arteries of patients who took Amaryl.

Additionally, compared with patients on Amaryl, those taking Actos experienced a 16% increase in HDL "good" cholesterol, a 15% drop in triglyceride levels, and a 45% drop in blood levels of a marker known as C-reactive protein that is associated with heart disease.

Past American Heart Association President Sidney Smith, MD, a cardiologist at the University of North Carolina at Chapel Hill, tells WebMD that the results are very encouraging.

But he says that he would not recommend that a person with diabetes switch treatments based on these results.

"The question now is whether the benefit will translate to improved outcomes," Smith says.

Nissen says that the study was not designed to determine whether Actos actually cuts the risk of heart attacks and stroke, but he thinks it "will translate into clinical benefits down the road."

Moving forward, he adds, "We can't just focus on pricking your finger and getting blood sugar down. The goal in diabetes therapy is to prevent complications. And the most feared complication is heart disease. I'm thrilled with results."

The study was funded by Takeda Pharmaceuticals, which manufactures Actos.

http://diabetes.webmd.com/news/10101/diabetes-drug-actos-slows-artery-plaque

邀请讨论

搜索

2008-04-01 15:28 浏览 : 629 回复 : 4

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 可沥滤物允许限量建立

楼主

胭脂

丁香园管理员

2楼

现在他们又要开香槟了
少了文迪雅这个强劲对手
现在又有这样的好事
想假装都不行

2008-04-01 15:29

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 中山三院上线统计（更新）

zhouxiaoyi81040

内分泌科

铁杆站友

3楼

本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。

2008-04-11 16:47

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 发热不止的老阿姨

zhouxiaoyi81040

内分泌科

铁杆站友

+1 积分
4楼

Diabetes Drug Actos Slows Artery Plaque
糖尿病药物艾可拓减慢动脉斑块形成
Study Shows Reduction in Atherosclerosis in Diabetes Patients
研究显示糖尿病患者的动脉粥样硬化减少
March 31, 2008 (Chicago) -- The diabetes pill Actos beat out an older diabetes drug, Amaryl, at slowing the buildup of plaque in the heart arteries of people with type 2 diabetes and cardiovascular disease, researchers report.
2008年3月31日（芝加哥）——研究人员报道，糖尿病药物艾可拓在减慢合并心血管疾病的2型糖尿病患者的心血管方面击败了一种糖尿病老药亚莫利。
Atherosclerosis, or plaque buildup in the inner lining of the arteries, is particularly aggressive in patients with diabetes, often leading to heart attacks and strokes. Nearly three-fourths of people with diabetes die from cardiovascular disease.
动脉粥样硬化，或者叫动脉内壁斑块形成，对于糖尿病患者极具威胁，常引起心脏病发作和中风。近四分之三的糖尿病患者死于心血管疾病。
"This represents, to our knowledge, the first demonstration of the ability of any blood-sugar-lowering agent to slow the progression of coronary atherosclerosis in patients with diabetes," says researcher Steven E. Nissen, MD, chairman of cardiovascular medicine at Cleveland Clinic.
“这是我们所了解的第一个证实具有减慢糖尿病患者冠脉粥样硬化发展作用的降糖药，”克利夫兰临床心血管药学主席，研究者Steven E. Nissen说。
"This will change the paradigm of how we treat people with diabetes," he tells WebMD. "It's not how much you lower blood sugar, but how you lower it."
“这会改变我们治疗糖尿病患者的模式，”他对WebMD说。“这不是你降低多少血糖的问题，而是你怎样降低血糖的问题。”
The study was presented at the annual meeting of the American College of Cardiology and simultaneously released online by The Journal of the American Medical Association.
这项研究在美国芝加哥心血管学会的年会上提出并同时被美国医药协会杂志在线发布。
How Actos and Amaryl Work
艾可拓和亚莫利怎样起效
Nissen and colleagues studied more than 350 people with type 2 diabetes and cardiovascular disease. About half were given Actos, a member of a relatively new class of antidiabetic agents known as thiazolidinediones.
Nissen和同事们研究了350多个合并心血管疾病的2型糖尿病患者。约一半给予艾可拓，一种新型的抗糖尿病药物，噻唑烷二酮类。
The rest were given Amaryl. It's a member of the class of agents known as sulfonylureas that have been available for decades and represent one of the most commonly prescribed classes of diabetic therapy.
其余的受试者给予亚莫利。亚莫利是磺脲类药物的一种，已经应用十来年，是糖尿病治疗处方中的最常用的药物中的一种。
All took medication for heart disease.
全体受试者都应用心血管药物。
Actos and Amaryl work very differently. Actos makes the body more sensitive to insulin. Amaryl stimulates the pancreas to release more insulin.
艾可拓和亚莫利作用非常不同。艾可拓增强胰岛素敏感性。亚莫利刺激胰腺分泌胰岛素。
Actos carries a "black box" warning that the drug may trigger heart failure, but it has not been linked to any increased risk of heart attack.
艾可拓背着一个“黑锅”，警告这种药物可能引起心衰，但是到目前为止并未发现它增加心脏事件的危险性。
Actos Slows Plaque Buildup
艾可拓减慢斑块形成
All the participants underwent ultrasounds at the start of the study and about 18 months later to determine changes in the plaque buildup within the coronary arteries.
所有受试者在研究开始时和18个月研究结束时都进行超声检查以确定冠脉血管内斑块形成的变化。
Results showed that Actos halted the dangerous progression of atherosclerosis and even started to reverse it, Nissen says. In contrast, plaque continued to build up in the arteries of patients who took Amaryl.
Nissen说，结果证实艾可拓阻止动脉粥样硬化的发展并甚至开始逆转这种趋势。相比之下，服用亚莫利的患者的动脉中斑块形成的脚步并未停顿。
Additionally, compared with patients on Amaryl, those taking Actos experienced a 16% increase in HDL "good" cholesterol, a 15% drop in triglyceride levels, and a 45% drop in blood levels of a marker known as C-reactive protein that is associated with heart disease.
此外，比起那些服用亚莫利的患者来说，服用艾可拓的患者的“好”胆固醇HDL上升了16%，而甘油三酯水平下降了15%，而且作为心脏疾病相关的标志物的C反应蛋白的水平下降了45%。
Past American Heart Association President Sidney Smith, MD, a cardiologist at the University of North Carolina at Chapel Hill, tells WebMD that the results are very encouraging.
前美国心脏协会主席MD Sidney Smith，一位美国北卡罗来纳查佩尔山大学的心脏学家对WebMD说这项结果很令人振奋。
But he says that he would not recommend that a person with diabetes switch treatments based on these results.
但是他也说道他并不会基于这些结果而建议糖尿病人改变治疗方案。
"The question now is whether the benefit will translate to improved outcomes," Smith says.
“现在的问题是这种益处会不会带来好的后果，”Smith说。
Nissen says that the study was not designed to determine whether Actos actually cuts the risk of heart attacks and stroke, but he thinks it "will translate into clinical benefits down the road."
Nissen说这项研究设计并不是旨在确定艾可拓是否确实降低心血管事件和中风的危险性，但他认为这种益处“接下来一定会带来更好的临床效益。”
Moving forward, he adds, "We can't just focus on pricking your finger and getting blood sugar down. The goal in diabetes therapy is to prevent complications. And the most feared complication is heart disease. I'm thrilled with results."
更进一步来讲，他说，“我们不能仅仅着眼于刺你的手指和降低你的血糖。糖尿病治疗的目的是阻止并发症。而最令人担心的并发症就是心脏病。这些结果使我很激动。”
The study was funded by Takeda Pharmaceuticals, which manufactures Actos.
该研究由生产艾可拓的武田制药赞助。

2008-04-11 20:26

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 2020中大考博，考免疫、内科、儿科、妇产的低分请进来

科技动态

【medical-news】文迪雅对手 Actos 能减少动脉硬化

提示

丁香园旗下网站

关于丁香园

官方链接

科技动态

分享到：

微信扫一扫

【medical-news】文迪雅对手 Actos 能减少动脉硬化

微信扫一扫

微信扫一扫

微信扫一扫

微信扫一扫

提示

丁香园旗下网站

关于丁香园

官方链接